Jazz Pharmaceuticals (JAZZ) Retained Earnings (2010 - 2026)

Jazz Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$651.0 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 162.91% year-over-year to -$651.0 million; the TTM figure through Mar 2026 stood at -$651.0 million (down 162.91% YoY), while the FY2025 annual figure was -$568.6 million, up 40.0% from the prior year.
• Retained Earnings for Q1 2026 stood at -$651.0 million, down from -$568.6 million in the prior quarter.
• The five-year high for Retained Earnings was $1.0 billion in Q1 2025, with the low at -$1.1 billion in Q2 2022.
• The 5-year median for Retained Earnings is -$569.9 million (2025), against an average of -$192.3 million.
• Peak annual rise in Retained Earnings reached 283.23% in 2022, while the deepest fall reached 220.43% in 2022.
• Jazz Pharmaceuticals' Retained Earnings stood at $733.6 million in 2022, then advanced by 19.78% to $878.7 million in 2023, then plunged by 207.85% to -$947.7 million in 2024, then soared by 40.0% to -$568.6 million in 2025, then declined by 14.49% to -$651.0 million in 2026.
• Business Quant data shows JAZZ's Retained Earnings at -$651.0 million in Q1 2026, -$568.6 million in Q4 2025, and -$569.9 million in Q3 2025.